-transparent.png){kind=logo}
Treatment of rats with experimental allergic neuritis with the beta 2-adrenergic agonist terbutaline suppresses clinical symptoms, decreases demyelination and Wallerian degeneration in peripheral nerves and improves electrophysiological parameters. Treatment is highly effective when given from the time of immunization through the acute phase of illness, when given for the first 12 days after immunization and also when given after the onset of the disease.
Related Publications
D H Kim, and
S Muthyala, and
B Soliven, and
K Wiegmann, and
R Wollmann, and
E Chelmicka-Schorr
December 1989,
Journal of neuroimmunology,
D H Kim, and
S Muthyala, and
B Soliven, and
K Wiegmann, and
R Wollmann, and
E Chelmicka-Schorr
January 1993,
International journal of immunopharmacology,
D H Kim, and
S Muthyala, and
B Soliven, and
K Wiegmann, and
R Wollmann, and
E Chelmicka-Schorr
November 1994,
Journal of neuropathology and experimental neurology,
D H Kim, and
S Muthyala, and
B Soliven, and
K Wiegmann, and
R Wollmann, and
E Chelmicka-Schorr
September 1987,
Brain research,
D H Kim, and
S Muthyala, and
B Soliven, and
K Wiegmann, and
R Wollmann, and
E Chelmicka-Schorr
January 1989,
Neuropathology and applied neurobiology,
D H Kim, and
S Muthyala, and
B Soliven, and
K Wiegmann, and
R Wollmann, and
E Chelmicka-Schorr
January 1989,
Experimental neurology,
D H Kim, and
S Muthyala, and
B Soliven, and
K Wiegmann, and
R Wollmann, and
E Chelmicka-Schorr
July 1979,
Journal of neuropathology and experimental neurology,
D H Kim, and
S Muthyala, and
B Soliven, and
K Wiegmann, and
R Wollmann, and
E Chelmicka-Schorr
July 1987,
Journal of the neurological sciences,
D H Kim, and
S Muthyala, and
B Soliven, and
K Wiegmann, and
R Wollmann, and
E Chelmicka-Schorr
January 1994,
Brain research bulletin,
D H Kim, and
S Muthyala, and
B Soliven, and
K Wiegmann, and
R Wollmann, and
E Chelmicka-Schorr
January 2000,
Neuropharmacology,
